Abstract |
The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.
|
Authors | G Santini, C De Souza, S Aversa, C Patti, L Tedeschi, M Candela, A Olivieri, T Chisesi, A Rubagotti, R Centurioni, V Nardi, M Congiu, M Gennaro, M Truini, Italian Non-Hodgkin's Lymphoma Co-operative Study Group |
Journal | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
(Braz J Med Biol Res)
Vol. 37
Issue 5
Pg. 719-28
(May 2004)
ISSN: 0100-879X [Print] Brazil |
PMID | 15107935
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bleomycin
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Italy
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prednisone
(administration & dosage, adverse effects)
- Prospective Studies
- Radiotherapy, Adjuvant
- Survival Analysis
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
|